Trial Profile

Canadian Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Nosocomial Acquired COVID-19 Patients

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bamlanivimab (Primary) ; Casirivimab/imdevimab (Primary) ; Sotrovimab (Primary)
Indications COVID 2019 infections; Nosocomial infections
Focus Therapeutic Use
Acronyms CATCO-NOS

Most Recent Events

14 Apr 2023 Status changed from suspended to discontinued.
30 Nov 2021 Status changed from recruiting to suspended.
28 Sep 2021 Sotrovimab intravenous infusion has been added to the study regimen.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com